M. Hernández Porto, T. Delgado, A. Aguirre-Jaime, M. J. Ramos, S. Campos, O. Acosta, Ana Belén Llanos, M. Lecuona
{"title":"Patients at Risk of Pulmonary Fibrosis Post Covid-19: Pulmonary Sequelae and Humoral Response","authors":"M. Hernández Porto, T. Delgado, A. Aguirre-Jaime, M. J. Ramos, S. Campos, O. Acosta, Ana Belén Llanos, M. Lecuona","doi":"10.26502/acbr.50170299","DOIUrl":null,"url":null,"abstract":"Background: The COVID-19 pandemic is one of the major public health problems. The aim of this study is to characterize patients hospitalized for COVID-19 pneumonia at risk of pulmonary fibrosis and to know the amount of protective antibodies and their permanence in these patients. Methods: Follow-up study of the humoral response in hospitalized patients at risk of pulmonary fibrosis post-COVID-19 who were followed up for one year after hospital discharge. Results: The study included 72 patients, 52 of whom had pre-existing chronic comorbidities. COVID-19 clinical severity was rated in 6% as mild, 58% as moderate and 36% as severe. After one year follow-up, forty percent had pulmonary sequelae, the most frequent being mild pulmonary fibrosis. All patients presented RBD IgG, 88% IgA after 8-9 months. The amount of RBD IgG was similar at 4-5 and 8-9 months post-COVID-19. There was no difference in RBD IgG level according to COVID-19 severity ( P = .441, P = .594). Conclusions: The amount of RBD IgG is maintained throughout the convalescent phase and could protect against new reinfections in patients at risk of pulmonary fibrosis Post Covid-19. However, it does not seem to predict the development or not of pulmonary fibrosis.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of clinical and biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/acbr.50170299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The COVID-19 pandemic is one of the major public health problems. The aim of this study is to characterize patients hospitalized for COVID-19 pneumonia at risk of pulmonary fibrosis and to know the amount of protective antibodies and their permanence in these patients. Methods: Follow-up study of the humoral response in hospitalized patients at risk of pulmonary fibrosis post-COVID-19 who were followed up for one year after hospital discharge. Results: The study included 72 patients, 52 of whom had pre-existing chronic comorbidities. COVID-19 clinical severity was rated in 6% as mild, 58% as moderate and 36% as severe. After one year follow-up, forty percent had pulmonary sequelae, the most frequent being mild pulmonary fibrosis. All patients presented RBD IgG, 88% IgA after 8-9 months. The amount of RBD IgG was similar at 4-5 and 8-9 months post-COVID-19. There was no difference in RBD IgG level according to COVID-19 severity ( P = .441, P = .594). Conclusions: The amount of RBD IgG is maintained throughout the convalescent phase and could protect against new reinfections in patients at risk of pulmonary fibrosis Post Covid-19. However, it does not seem to predict the development or not of pulmonary fibrosis.